ESSA Pharma Inc (EPIX) - Net Assets
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has net assets worth $108.90 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($110.50 Million) and total liabilities ($1.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EPIX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $108.90 Million |
| % of Total Assets | 98.55% |
| Annual Growth Rate | 159.99% |
| 5-Year Change | 57.24% |
| 10-Year Change | 2713.43% |
| Growth Volatility | 10941.51 |
ESSA Pharma Inc - Net Assets Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore EPIX total assets for the complete picture of this company's asset base.
Annual Net Assets for ESSA Pharma Inc (2012–2024)
The table below shows the annual net assets of ESSA Pharma Inc from 2012 to 2024. For live valuation and market cap data, see EPIX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $124.61 Million | -14.44% |
| 2023-09-30 | $145.63 Million | -12.86% |
| 2022-09-30 | $167.12 Million | -13.86% |
| 2021-09-30 | $194.01 Million | +144.82% |
| 2020-09-30 | $79.24 Million | +61.13% |
| 2019-09-30 | $49.18 Million | +437.38% |
| 2018-09-30 | $9.15 Million | +314.13% |
| 2017-09-30 | $-4.27 Million | -695.90% |
| 2016-09-30 | $-537.00K | -112.12% |
| 2015-09-30 | $4.43 Million | +124.35% |
| 2014-09-30 | $1.97 Million | +312.10% |
| 2013-09-30 | $479.04K | +36570.88% |
| 2012-09-30 | $1.31K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ESSA Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20800105982.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $279.86 Million | 224.60% |
| Other Comprehensive Income | $-2.06 Million | -1.66% |
| Other Components | $54.81 Million | 43.99% |
| Total Equity | $124.61 Million | 100.00% |
ESSA Pharma Inc Competitors by Market Cap
The table below lists competitors of ESSA Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Imunon Inc
NASDAQ:IMNN
|
$9.52 Million |
|
Great Western Exploration Ltd
AU:GTE
|
$9.54 Million |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
$9.54 Million |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
$9.54 Million |
|
Viking Mines Ltd
AU:VKA
|
$9.52 Million |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
$9.51 Million |
|
Bhakti Agung Propertindo
JK:BAPI
|
$9.50 Million |
|
Organoclick AB
ST:ORGC
|
$9.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ESSA Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 145,627,060 to 124,605,770, a change of -21,021,290 (-14.4%).
- Net loss of 28,542,821 reduced equity.
- Other comprehensive income increased equity by 57,131.
- Other factors increased equity by 7,464,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.54 Million | -22.91% |
| Other Comprehensive Income | $57.13K | +0.05% |
| Other Changes | $7.46 Million | +5.99% |
| Total Change | $- | -14.44% |
Book Value vs Market Value Analysis
This analysis compares ESSA Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1128.43x to 0.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-09-30 | $0.00 | $0.20 | x |
| 2013-09-30 | $0.61 | $0.20 | x |
| 2014-09-30 | $2.52 | $0.20 | x |
| 2015-09-30 | $4.83 | $0.20 | x |
| 2016-09-30 | $-0.40 | $0.20 | x |
| 2017-09-30 | $-2.94 | $0.20 | x |
| 2018-09-30 | $2.00 | $0.20 | x |
| 2019-09-30 | $5.83 | $0.20 | x |
| 2020-09-30 | $3.53 | $0.20 | x |
| 2021-09-30 | $5.04 | $0.20 | x |
| 2022-09-30 | $3.79 | $0.20 | x |
| 2023-09-30 | $3.30 | $0.20 | x |
| 2024-09-30 | $2.81 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ESSA Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-22.91%) is above the historical average (-75.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -148.35% | 0.00% | 0.00x | 1.10x | $-2.07K |
| 2013 | -286.27% | 0.00% | 0.00x | 1.37x | $-1.42 Million |
| 2014 | -92.39% | 0.00% | 0.00x | 2.13x | $-2.02 Million |
| 2015 | -193.46% | 0.00% | 0.00x | 1.69x | $-9.01 Million |
| 2016 | 0.00% | -6055299.54% | 0.00x | 0.00x | $-13.09 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.07 Million |
| 2018 | -127.08% | 0.00% | 0.00x | 1.75x | $-12.55 Million |
| 2019 | -21.23% | 0.00% | 0.00x | 1.11x | $-15.36 Million |
| 2020 | -29.59% | 0.00% | 0.00x | 1.02x | $-31.37 Million |
| 2021 | -18.97% | 0.00% | 0.00x | 1.02x | $-56.21 Million |
| 2022 | -21.00% | 0.00% | 0.00x | 1.01x | $-51.81 Million |
| 2023 | -18.25% | 0.00% | 0.00x | 1.02x | $-41.15 Million |
| 2024 | -22.91% | 0.00% | 0.00x | 1.03x | $-41.00 Million |
Industry Comparison
This section compares ESSA Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ESSA Pharma Inc (EPIX) | $108.90 Million | -148.35% | 0.01x | $9.52 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.